10-K: Dyne Therapeutics Advances Neuromuscular Pipeline with Strong Clinical Data and Funding

Dyne Therapeutics reports significant clinical progress for DMD and DM1 programs, secures substantial financing, and expands its pipeline for genetically driven neuromuscular diseases.

Summary

• Dyne Therapeutics is a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases using its proprietary FORCE platform.
• The FORCE platform leverages transferrin receptor 1 (TfR1) to deliver targeted therapeutics to muscle tissue and the central nervous system (CNS).
• The company's pipeline includes product candidates for Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1), facioscapulohumeral dystrophy (FSHD), and Pompe disease.
• Z-rostudirsen (DYNE-251) for DMD (exon 51 skipping) is in a global Phase 1/2 DELIVER trial, which is designed to be registrational.
• In December 2025, the DELIVER trial met its primary endpoint, demonstrating a statistically significant increase in muscle content-adjusted dystrophin (mean absolute expression of 5.46% of normal, p<0.0001).
• Functional improvement was observed across multiple clinical endpoints in the DELIVER Registrational Expansion Cohort (REC), including RFF Velocity and 10-Meter Walk/Run Velocity, which improved relative to placebo (nominal p<0.05). Lung function remained stable.
• Z-basivarsen (DYNE-101) for DM1 is being evaluated in the global Phase 1/2 ACHIEVE trial, also designed to be registrational.
• In January 2025, the ACHIEVE trial reported significant splicing correction at 3 months and robust, sustained improvement in myotonia (vHOT improved by 3.3 seconds compared to placebo at 6 months) and other functional endpoints at up to 12 months.
• Preclinical data for DYNE-302 (FSHD) showed robust and durable DUX4 suppression and functional benefit in a mouse model.
• Preclinical data for DYNE-401 (Pompe disease) demonstrated glycogen clearance in muscle and CNS, normalized lysosomal size, and superior dose potency compared to GAA alone, supporting potential for monthly dosing.
• The company reported net losses of $446.2 million for the year ended December 31, 2025, compared to $317.4 million in 2024 and $235.9 million in 2023.
• As of December 31, 2025, the accumulated deficit was $1.4 billion.
• Cash, cash equivalents, and marketable securities totaled $1.1 billion as of December 31, 2025.
• The company believes its existing capital resources will fund operating expenses, debt service, and capital expenditure requirements into the first quarter of 2028.
• In 2025, the company raised $140.6 million net from an at-the-market offering, $215.8 million net from a follow-on public offering in July, and $377.7 million net from another follow-on public offering in December.
• The company secured $148.3 million net from the first two tranches of a $275.0 million term loan agreement with Hercules Capital in 2025.
• A global cross-license agreement with Avidity Biosciences, Inc. for certain patent rights was entered into in December 2025.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong positive report, driven by significant clinical trial successes for its lead candidates in DMD and DM1, which demonstrate superior efficacy compared to existing or developing therapies, coupled with substantial capital raises that extend its financial runway.

Positives

• Z-rostudirsen (DMD) DELIVER trial met its primary endpoint, showing a statistically significant increase in muscle content-adjusted dystrophin (mean absolute expression of 5.46% of normal, p<0.0001).
• Functional improvement was observed in DELIVER REC across multiple clinical endpoints, including RFF Velocity and 10-Meter Walk/Run Velocity, which improved relative to placebo (nominal p<0.05).
• Lung function (Forced Vital Capacity Percent Predicted) remained stable in DELIVER REC, showing clear separation from placebo.
• Long-term results from DELIVER MAD cohorts demonstrated sustained functional improvement across multiple endpoints out to 24 months.
• Z-rostudirsen exhibited a favorable safety profile in the DELIVER trial, with most related treatment emergent adverse events (TEAEs) being mild or moderate, and no related serious TEAEs in the REC.
• Z-rostudirsen received Breakthrough Therapy, Fast Track, and Rare Pediatric Disease designations from the FDA, and Orphan Drug designation from the FDA, EMA, and Japanese Ministry of Health, Labour and Welfare.
• Z-basivarsen (DM1) ACHIEVE trial demonstrated robust splicing correction at 3 months and early, robust, and sustained improvement in myotonia (vHOT improved by 3.3 seconds compared to placebo at 6 months) and other functional endpoints (10-Meter Walk/Run Test, 5 Times Sit to Stand Test, Myotonic Dystrophy Health Index, Qualitative Muscle Testing) at up to 12 months.
• Z-basivarsen showed improvement in patient-reported outcomes, including measurements of CNS manifestations of DM1.
• Z-basivarsen demonstrated a favorable safety profile in the ACHIEVE trial, with most TEAEs being mild or moderate, and no related serious TEAEs.
• Z-basivarsen received Breakthrough Therapy, Orphan Drug, and Fast Track designations by the FDA, and Orphan Drug designation by the EMA and Japanese Ministry of Health, Labour and Welfare.
• DYNE-302 (FSHD) preclinical data showed robust and durable DUX4 suppression and functional benefit, including prevention and reversal of muscle weakness, in a mouse model.
• DYNE-401 (Pompe disease) preclinical data demonstrated glycogen clearance in muscle and CNS, normalized lysosomal size, and superior dose potency compared to GAA alone, supporting potential for monthly dosing.
• Strong liquidity position with $1.1 billion in cash, cash equivalents, and marketable securities as of December 31, 2025.
• Successfully raised significant capital through follow-on public offerings ($593.5 million net) and an at-the-market offering ($140.6 million net) in 2025.
• Secured additional debt financing of $148.3 million net from Hercules Capital in 2025, with potential for further tranches up to $275.0 million.
• Entered into a global cross-license agreement with Avidity Biosciences, Inc. for certain patent rights, indicating strategic collaboration and intellectual property strength.
• Management concluded that internal control over financial reporting was effective as of December 31, 2025.

Negatives

• Incurred significant operating losses: $446.2 million in 2025, $317.4 million in 2024, and $235.9 million in 2023.
• Accumulated deficit of $1.4 billion as of December 31, 2025.
• No products approved for sale and no revenue generated from product sales to date.
• Expects to incur significant expenses and operating losses for the foreseeable future.
• Will need substantial additional funding beyond the first quarter of 2028 to support continuing operations and growth strategy.
• The Loan Agreement with Hercules Capital contains restrictive and financial covenants (Minimum Cash Covenant, Minimum Revenue Covenant) that may limit operating flexibility.
• Dependence on a small number of third-party suppliers for the manufacture of Fab, linkers, and payloads, posing supply chain risks.
• The biotechnology and biopharmaceutical industries are highly competitive, with many competitors possessing greater financial resources and expertise.
• The company's stock price has been, and is likely to continue to be, volatile.
• Incurred increased costs and management time due to operating as a public company, especially no longer being an emerging growth company or smaller reporting company.

Risks

• The company will need substantial additional funding, and if unable to raise capital when needed, product development programs or commercialization efforts could be delayed, reduced, or eliminated.
• Product candidates are in varying stages of preclinical and clinical development, and the company does not expect to have a product ready for commercialization until at least 2027, if ever.
• Substantial delays may be encountered in the commencement, enrollment, or completion of clinical trials, and data may fail to demonstrate sufficient safety and efficacy.
• The company's FORCE platform approach to discovery and development is unproven, and efforts to develop product candidates may not be successful.
• The outcome of preclinical studies and initial data from earlier-stage clinical trials may not be predictive of final results or future clinical trials.
• Product candidates may cause undesirable side effects or have other unexpected adverse properties, which could delay or prevent regulatory approval or limit commercial potential.
• The Loan Agreement contains restrictive and financial covenants (e.g., Minimum Cash Covenant, Minimum Revenue Covenant) that may limit operating flexibility, and failure to comply could result in a default.
• Reliance on third parties to conduct product manufacturing, research, preclinical, and clinical testing, who may not perform satisfactorily.
• Substantial competition from other companies developing products for muscle diseases, potentially leading to others commercializing products before or more successfully than the company.
• Rights to develop and commercialize certain product candidates are subject to third-party licenses, and failure to comply with obligations could lead to loss of intellectual property rights.
• Inability to obtain, maintain, and defend patent and other intellectual property protection, or if the scope is not sufficiently broad, competitors could develop and commercialize similar products.
• Expending limited resources to pursue a particular program or product candidate may lead to failure to capitalize on more profitable opportunities.
• Clinical trial and product liability lawsuits could divert resources, incur substantial liabilities, and limit commercialization.
• Dependence on single-source suppliers for some components and materials, leading to potential supply disruptions.
• Collaborations with third parties for research, development, and commercialization may not be successful.
• Conflicts may arise between the company and its potential collaborators.
• Inability to establish sales, marketing, and distribution capabilities or enter into agreements with third parties.
• Biologic product candidates may face competition sooner than anticipated due to biosimilar pathways.
• Approved product candidates may fail to achieve market acceptance by physicians, patients, and third-party payers.
• Market opportunities for product candidates may be smaller than believed, adversely affecting revenue.
• Inability to obtain adequate coverage and reimbursement for product candidates.
• Relationships with healthcare providers, physicians, and third-party payers are subject to anti-kickback, fraud and abuse, and other healthcare laws and regulations.
• Legislative and regulatory changes (e.g., healthcare reform, drug pricing) may increase the difficulty and cost of obtaining reimbursement.
• Subject to stringent privacy and data security laws (e.g., HIPAA, CCPA, CPRA, GDPR), and failure to comply could result in significant fines and penalties.
• Employees, principal investigators, consultants, and commercial partners may engage in misconduct or other improper activities.
• Laws and regulations governing international operations may preclude development/sales outside the U.S. or impact business, and changes in U.S. trade policy could have an adverse impact.
• Failure to comply with environmental, health, and safety laws and regulations could lead to fines or significant costs.
• Disruptions at the FDA and other government agencies (e.g., funding cuts, personnel losses, government shutdowns) could hinder timely approval of product candidates.
• Future success depends on the ability to retain key executives and to attract, retain, and motivate qualified personnel.
• Difficulties in managing growth as the company expands its development and regulatory capabilities.
• Future acquisitions or strategic alliances could disrupt business and harm financial condition.
• Internal information technology systems, or those of vendors, collaborators, or consultants, may fail or suffer security breaches, leading to disruptions or compromise of sensitive information.
• Operations or those of third parties might be affected by natural disasters, pandemics, or other catastrophic events.
• The price of common stock is volatile and fluctuates substantially.
• Unfavorable global economic conditions could adversely affect business.
• Executive officers and directors and their affiliates have the ability to significantly influence matters submitted to stockholders for approval.
• Broad discretion in the use of cash, cash equivalents, and marketable securities, which may not be used effectively.
• No anticipated cash dividends on capital stock in the foreseeable future.
• A significant portion of total outstanding shares may be sold into the market in the near future, potentially causing the market price to drop.
• Incurred and will continue to incur increased costs as a result of operating as a public company, and management will devote substantial time to new compliance initiatives.
• Failure to maintain an effective system of internal control over financial reporting could lead to inaccurate financial reports or fraud.
• Provisions in corporate charter documents and under Delaware law could make an acquisition of the company more difficult and may prevent attempts by stockholders to replace or remove current management.
• The restated certificate of incorporation designates specific judicial forums for certain actions, which could limit stockholders' ability to obtain a favorable judicial forum.
• Changes in patent law in the United States or worldwide could diminish the value of patents.
• Claims challenging the inventorship or ownership of patent and other intellectual property rights.
• Reliance on third parties requires sharing trade secrets, increasing the possibility of discovery or misappropriation.

Future Outlook

The company plans to submit a Biologics License Application (BLA) to the FDA for U.S. Accelerated Approval of z-rostudirsen for DMD (exon 51 skipping) in Q2 2026, with a potential U.S. launch in Q1 2027, assuming priority review and FDA approval. A global confirmatory Phase 3 clinical trial for z-rostudirsen is planned for Q2 2026. For z-basivarsen (DM1), a BLA submission for U.S. Accelerated Approval is planned for early Q3 2027, with a potential U.S. launch in Q1 2028, contingent on favorable data, priority review, and FDA approval. A global confirmatory Phase 3 clinical trial for z-basivarsen is set to begin in March 2026. The company is also progressing DYNE-302 (FSHD) and DYNE-401 (Pompe) toward clinical development and intends to expand its portfolio to additional indications, including CNS, rare skeletal muscle, and cardiac and metabolic muscle diseases. Expenses are expected to increase substantially as clinical development advances and commercialization efforts begin, with existing capital projected to fund operations into Q1 2028, necessitating additional future funding.

Management Comments

• Our shared definition of success is simple: we do what we say we are going to do. We keep our commitments to patients, employees and other Dyne stakeholders.
• We endeavor to act with integrity and transparency.
• We believe that PMOs, with their preferential targeting of nuclear mechanisms, are the best payload to address nuclear exon skipping.
• We believe our Fab targeting TfR1 allows for more efficient delivery of a PMO to skeletal, cardiac and smooth muscle cells, creating an opportunity to increase dystrophin expression, enable less frequent dosing and provide greater clinical benefit compared to current therapeutic approaches.
• We believe that serum stability is necessary to enable systemic intravenous administration, stability of the conjugated oligonucleotide in the bloodstream, delivery to muscle tissue and internalization of the therapeutic payload in the muscle cells.
• We believe that our linker and conjugation chemistry will enable us to rapidly design, produce and screen molecules to enable new muscle disease programs.
• We believe that the patient population is currently underdiagnosed due to lack of available therapies as is observed for other rare diseases.
• We believe that the introduction of new therapies for DM1 will cause the diagnosis rate to improve, resulting in an increase in the overall prevalence estimates for the disease.
• We expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for any product candidates we may develop or additional pricing pressures.

Industry Context

StockSavvy.ai notes that Dyne Therapeutics operates in the highly competitive and rapidly evolving biotechnology and biopharmaceutical industries, specifically the muscle disease field. The company's FORCE platform, designed for targeted delivery to muscle and CNS, aims to address limitations in existing therapies, particularly for Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1). The positive clinical data for z-rostudirsen (DMD) showing best-in-class dystrophin expression and functional improvements, and for z-basivarsen (DM1) demonstrating robust splicing correction and myotonia improvement, position Dyne favorably against competitors. However, the market includes established players like Sarepta Therapeutics (EXONDYS 51, VYONDYS 53, AMONDYS 45, ELEVIDYS), Nippon Shinyaku (VILTEPSO), PTC Therapeutics (EMFLAZA), Catalyst Pharmaceuticals (AGAMREE), and Amicus Therapeutics (Pombiliti + Opfolda for Pompe). Emerging competitors like Avidity Biosciences (delpacibart zotadirsen, delpacibart etedesiran, delpacibart braxlosiran) also utilize antibody-oligonucleotide conjugates, indicating a growing trend in targeted delivery. The company's expansion into FSHD and Pompe disease, where unmet needs remain high despite existing enzyme replacement therapies for Pompe, aligns with industry efforts to develop disease-modifying treatments for rare genetic disorders. The cross-license agreement with Avidity Biosciences suggests a strategic approach to intellectual property in a competitive landscape.

Comparison to Industry Standards

• Z-rostudirsen (DMD) demonstrated a mean absolute dystrophin expression of 5.46% of normal in its DELIVER trial. This compares favorably to existing FDA-approved naked PMO-based oligonucleotide therapies such as EXONDYS 51 (eteplirsen), VYONDYS 53 (golodirsen), and AMONDYS 45 (casimersen), which have shown less than 1% mean increase in dystrophin, and VILTEPSO (vitolarsen), which has demonstrated approximately 5% increase in dystrophin.
• For DM1, z-basivarsen demonstrated robust splicing correction and sustained improvement in myotonia (vHOT improved by 3.3 seconds vs. placebo at 6 months) and other functional endpoints. This is significant as there are currently no disease-modifying therapies approved for DM1. A direct competitor, delpacibart etedesiran (Avidity Biosciences), an antibody-linked siRNA, is in Phase 3 clinical trials.
• For FSHD, there are currently no approved therapies. DYNE-302's preclinical data showing robust DUX4 suppression and functional benefit positions it against other therapies in development, such as ARO-DUX4 (Arrowhead/Sarepta) in Phase 3 and delpacibart braxlosiran (Avidity) in Phase 1/2.
• For Pompe disease, DYNE-401 aims to improve upon existing enzyme replacement therapies (Myozyme/Lumizyme, Nexviazyme/Nexviadyme, Pombiliti + Opfolda) which have inadequate efficacy in skeletal muscle and limited CNS penetration. DYNE-401's preclinical data showing glycogen clearance in muscle and CNS and superior dose potency suggests a potential advantage over current standards of care.

Management Changes

Corporate Governance

Legal Proceedings

• Not currently subject to any material legal proceedings.

Related Party Transactions

• Atlas Venture and related affiliated entities were beneficial owners of approximately 5.5% of the company's outstanding common stock as of December 31, 2025.
• On January 27, 2025, Atlas Venture and related affiliated entities purchased 1,111,111 shares of common stock for $15.0 million in an at-the-market offering at the prevailing market price.
• The chairman of the company's board of directors is a partner at Atlas Venture.

Stakeholder Impact

• Shareholders: Potential for significant returns due to strong clinical data and pipeline progress, but also face risks of dilution from future capital raises and stock price volatility. The influence of executive officers, directors, and affiliates on corporate matters is noted.
• Patients: Significant positive impact through the development of life-transforming therapeutics for genetically driven neuromuscular diseases (DMD, DM1, FSHD, Pompe), addressing high unmet medical needs.
• Employees: Opportunities for growth and development within a patient-focused culture, supported by competitive compensation and benefits. Risk of loss of key personnel is acknowledged.
• Customers/Healthcare Providers: Introduction of new, potentially superior therapeutic options for severe diseases. However, challenges related to market acceptance, pricing, and reimbursement will need to be navigated.
• Suppliers/Creditors: Continued business with third-party manufacturers and suppliers, but with inherent risks of supply chain disruptions. The company's obligations under the Hercules Capital Loan Agreement are a key consideration for creditors.

Next Steps

• Submit a Biologics License Application (BLA) to the FDA for U.S. Accelerated Approval of z-rostudirsen (DMD) in Q2 2026.
• Initiate a global confirmatory Phase 3 clinical trial of z-rostudirsen (DMD) in Q2 2026.
• Pursue approval pathways outside of the United States for z-rostudirsen.
• Complete enrollment in the ACHIEVE Registrational Expansion Cohort (DM1) in Q2 2026.
• Initiate a global confirmatory Phase 3 clinical trial of z-basivarsen (DM1) in March 2026.
• Obtain data from the ACHIEVE Registrational Expansion Cohort (DM1) in Q1 2027.
• Submit a BLA to the FDA for U.S. Accelerated Approval of z-basivarsen (DM1) early in Q3 2027.
• Pursue approval pathways outside of the United States for z-basivarsen.
• Progress DYNE-302 (FSHD) toward clinical development.
• Progress DYNE-401 (Pompe) toward clinical development.
• Advance four development candidates (DYNE-253, DYNE-245, DYNE-244, DYNE-255) for DMD (exons 53, 45, 44, 55) into IND-enabling studies.
• Expand pipeline to additional product candidates and indications (CNS, rare skeletal muscle, cardiac and metabolic muscle diseases).
• Selectively enter into strategic collaborations.
• Continue building a team and enhancing the FORCE platform.
• File a definitive proxy statement relating to the 2026 Annual Meeting of Stockholders within 120 days of December 31, 2025.
• Continue to evaluate and enhance cybersecurity capabilities.

Key Dates

Recommendation

The company has reported highly positive clinical data for its lead candidates in DMD and DM1, demonstrating superior efficacy compared to existing treatments or those in development. These results, combined with multiple expedited regulatory designations (Breakthrough, Fast Track, Orphan Drug) and a clear path to potential accelerated approval and commercial launch in 2027-2028, significantly de-risk the pipeline. Furthermore, substantial capital raises have bolstered the balance sheet, providing a runway into Q1 2028, which is crucial for continued development and commercialization efforts. While significant losses persist and competition is present, the strong clinical performance and strategic financial positioning indicate a compelling investment opportunity.

Keywords

Dyne Therapeutics, Neuromuscular diseases, Duchenne muscular dystrophy, Myotonic dystrophy type 1, Facioscapulohumeral dystrophy, Pompe disease, FORCE platform, Z-rostudirsen, DYNE-251, Z-basivarsen, DYNE-101, Clinical trials, FDA Accelerated Approval, Orphan Drug, Breakthrough Therapy, Fast Track, Biologics License Application, Gene therapy, Oligonucleotide therapeutics, Financial results, Biotechnology, Pharmaceutical, Drug development, Rare diseases, Intellectual property, Hercules Capital, Equity financing, Debt financing, SEC filing